Charles Darwin University

CDU eSpace
Institutional Repository

CDU Staff and Student only

'Simply stunning' - trastuzumab in HER2-positive breast cancer

Doggrell, SA (2006). 'Simply stunning' - trastuzumab in HER2-positive breast cancer. Expert Opinion on Pharmacotherapy,7(5):631-634.

Document type: Journal Article
Citation counts: Scopus Citation Count Cited 3 times in Scopus Article | Citations

Google Scholar Search Google Scholar

Title 'Simply stunning' - trastuzumab in HER2-positive breast cancer
Author Doggrell, SA
Journal Name Expert Opinion on Pharmacotherapy
Publication Date 2006
Volume Number 7
Issue Number 5
ISSN 1465-6566   (check CDU catalogue open catalogue search in new window)
Scopus ID 2-s2.0-33645804772
Start Page 631
End Page 634
Total Pages 4
HERDC Category C1 - Journal Article (DEST)
Abstract Human epidermal growth factor receptor-2 (HER-2)-positive metastatic breast cancer is a more aggressive disease than HER-2-negative metastatic breast cancer. The initial Phase III trial with the HER-2 antibody, trastuzumab, in this cancer suggested that, although trastuzumab was beneficial, cardiac adverse events would prevent it from being widely used. Recently trials suggest that, with close monitoring of left ventricular ejection fraction, trastuzumab can be used concurrently or sequentially with the standard adjuvant treatment of HER-2-positive metastatic breast cancer with good benefit. Therefore, with appropriate regimens, trastuzumab will be able to be used routinely in the treatment of HER-2-positive metastatic breast cancer.
Keywords anthracyclines
her-2-positive metastatic breast cancer
adjuvant chemotherapy
DOI   (check subscription with CDU E-Gateway service for CDU Staff and Students  check subscription with CDU E-Gateway in new window)
Version Filter Type
Access Statistics: 139 Abstract Views  -  Detailed Statistics
Created: Wed, 28 Nov 2007, 14:16:08 CST